Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: NORVASC

« Back to Dashboard
Norvasc is a drug marketed by Pfizer and is included in one NDA. It is available from twelve suppliers.

The generic ingredient in NORVASC is amlodipine besylate. There are forty-seven drug master file entries for this compound. Twelve suppliers are listed for this compound. There are five tentative approvals for this compound. Additional details are available on the amlodipine besylate profile page.

Summary for Tradename: NORVASC

Patents:0
Applicants:1
NDAs:1
Suppliers: see list12

Pharmacology for Tradename: NORVASC

Clinical Trials for: NORVASC

CKD-330 Drug-Drug Interaction Study (Amlodipine)
Status: Completed Condition: Hypertension

Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension
Status: Completed Condition: Hypertension

A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Tablets Under Fed Conditions
Status: Completed Condition: Healthy

A Relative Bioavailability Study of Amlodipine Besylate 10 mg Tablets Under Fasting Conditions
Status: Completed Condition: Healthy

Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension
Status: Completed Condition: Hypertension

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension
Status: Completed Condition: Hypertension

Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy
Status: Recruiting Condition: Hypertension

Amlodipine 10mg Drug Use Investigation
Status: Completed Condition: Hypertension

Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5/50 and FDC5/100 Under Fasting Conditions
Status: Completed Condition: Hypertension

Bioequivalency Study of Amlodipine Besylate Tablets, 10 mg of Dr. Reddy's Under Fed Conditions
Status: Completed Condition: Healthy

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer
NORVASC
amlodipine besylate
TABLET;ORAL019787-001Jul 31, 1992RXNo<disabled><disabled>
Pfizer
NORVASC
amlodipine besylate
TABLET;ORAL019787-002Jul 31, 1992RXNo<disabled><disabled>
Pfizer
NORVASC
amlodipine besylate
TABLET;ORAL019787-003Jul 31, 1992RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc